Nuwellis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nuwellis, Inc. on June 17, 2026, reporting events occurring on June 16, 2026. The filing addresses significant changes to the Company's executive leadership and Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- CEO Departure: John L. Erb resigned as Chief Executive Officer, effective June 30, 2026. His resignation was not the result of any dispute with the Company or the Board. He will continue to serve as Chairman of the Board.
- CEO Appointment: Michael McCormick was appointed Chief Executive Officer, President, and a member of the Board of Directors, effective June 30, 2026.
- Board Expansion: The Board size increased from five to six members to accommodate Mr. McCormick's appointment.
Management Commentary and Compensation
Mr. McCormick brings over 30 years of experience in medical device leadership, including prior roles as CEO of Osprey Medical and Anulex Technologies. He has served as a consultant and Chief Commercial Officer for Nuwellis since September 2025.
Compensation Arrangements:
- Base Salary: $431,100 annually, effective June 30, 2026.
- Incentive Compensation: Targeted at 65% of base salary, prorated for 2026.
- Equity Grant: A one-time grant is expected within 90 days of joining; specific terms were not determined at the time of filing.
- Contract Term: 12 months, renewable by mutual agreement.
Investor Verification Checklist
- Verify the specific terms of the one-time equity grant for Mr. McCormick once the Compensation Committee finalizes them (expected within four business days of determination).
- Review the full text of the Employment Agreement referenced in the filing for additional covenants or termination provisions.
- Monitor future filings for the transition plan between Mr. Erb and Mr. McCormick to ensure operational continuity.
- Confirm the impact of this leadership change on the Company's strategic direction and commercial execution.